Real-Time vs Accelerated Stability for Cu-Peptide Actives — What ICH Q1A Says and Doesn't

The standard cosmetic-industry stability protocol borrows liberally from ICH Q1A — long-term storage at 25 °C, accelerated at 40 °C, sometimes with humidity control. The framework is sound for most stable cosmetic ingredients. For Cu-peptide actives the application needs nuance: the temperature dependence of Cu-peptide complex dissociation is not Arrhenius-linear across the full ICH range, and the most operationally useful data lives at the specific carrier chemistry of the finished product rather than in generic aqueous conditions.

This Note covers what the standard accelerated framework actually tells you about Cu-peptide stability, where it misleads, and what the atelier ships for stability documentation.

What ICH Q1A actually specifies

ICH Q1A(R2) defines stability testing conditions for pharmaceutical drug substances and products. For room-temperature-stored materials, the long-term condition is 25 °C ± 2 °C / 60% RH ± 5% RH for ≥ 12 months with 0/3/6/9/12/18/24-month pulls. The accelerated condition is 40 °C ± 2 °C / 75% RH ± 5% RH for ≥ 6 months with 0/3/6-month pulls. The intermediate condition (30 °C / 65% RH) is also defined.

These conditions are not specific to cosmetic actives, but the cosmetic industry has substantially adopted them as the practical standard. ISO 22716 (Good Manufacturing Practice for cosmetics) references stability testing in general terms; the operational protocols largely follow the ICH framework.

Why Cu-peptide complicates the Arrhenius extrapolation

The standard accelerated-stability logic: degradation rate doubles roughly every 10 °C (Arrhenius approximation); a 6-week study at 40 °C predicts about 6-12 months of real-time storage at 25 °C. For most cosmetic actives this works well enough.

For Cu-peptide complexes, three complications:

• **The complex equilibrium itself is temperature-dependent.** Higher temperature shifts the equilibrium toward dissociated forms (the entropy of the dissociated state is higher). At 40 °C the system is materially more dissociated than at 25 °C; the 'degradation' measured at 40 °C is partly equilibrium shift, partly irreversible degradation. Arrhenius assumes constant equilibrium; that assumption fails here.
• **Above 50-60 °C, dissociation kinetics change qualitatively.** The activation energy for Cu-peptide dissociation increases sharply above approximately 50 °C; data from 60 °C does not Arrhenius-extrapolate to 25 °C reliably.
• **Carrier chemistry interacts non-linearly with temperature.** A formulation containing trace metals or chelators that are stable at 25 °C may release or activate at 40 °C, accelerating Cu-peptide dissociation through a mechanism that doesn't exist at lower temperature. The accelerated data over-predicts real-time degradation.

What stability data is operationally useful

For Cu-peptide actives, the most useful stability data:

• **Real-time at 25 °C in the actual formulation matrix** — long-pull (0/3/6/12/18/24 months) of the actual product on actual market shelves. This is the only data that directly predicts product behaviour.
• **Accelerated at 40 °C / 75% RH for 4-8 weeks in the actual formulation matrix** — useful for fast screening of formulation candidates, with the explicit understanding that 40 °C results over-predict the real-time degradation for Cu-peptides specifically.
• **Real-time at 25 °C in the raw active (lyophilate or aqueous solution) in chelator-free water** — useful for distinguishing active-stability from carrier-stability issues. If the lyophilate is stable for 24 months at 25 °C but the formulated product degrades in 6 months, the carrier is the issue.
• **Light-stress and freeze-thaw** — discrete stress protocols that target known Cu-peptide failure modes (UV-induced oxidation, freeze-thaw-induced precipitation). These are not part of standard ICH but are operationally useful.

What Cupratec ships and what's documented under NDA

Standard Cupratec release reports include real-time stability data at 25 °C in chelator-free water for the released lot, at 0/2/4/12/24 weeks. The accelerated condition (40 °C / 75% RH) is run on representative lots and the data is held on file rather than printed on every COA.

Available on request under NDA:

• Real-time stability at 25 °C in formulator-supplied carrier matrix, with extended timeline (12-24 months pulls)
• Accelerated stability at 40 °C and 60 °C, with explicit caveats on Arrhenius extrapolation limits for Cu-peptide systems
• Light-stress data per ICH Q1B (photostability) on the formulated product
• Freeze-thaw cycle data for products with cold-chain or temperature-excursion exposure
• Specific stability data in the presence of common cosmetic excipients (ascorbic acid at typical concentrations, niacinamide, sun-filter chemistries)

ICH Q1A is a starting framework, not a complete answer for Cu-peptide stability. The atelier provides the data that the framework formally specifies, plus the carrier-and-excipient-specific data that actually predicts product behaviour in the buyer's formulation.